Scailyte AG

https://www.scailyte.com

LinkedIn: https://www.linkedin.com/company/scailyte

Scailyte is a spin-off of ETH Zurich and combines single-cell technologies, high-quality datasets and machine learning methods to identify disease-specific biomarkers, with a focus on oncology and immunology. Scailyte’s proprietary best-in-class data analysis platform ScaiVision associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, in order to identify ultra-sensitive biomarker signatures. Thanks to the single-cell resolution and AI-driven approach, ScaiVision is the most powerful and cutting-edge approach to precise diagnosis and prediction of therapy response. Scailyte leverages a broad network of top clinicians to identify clinical indications with high unmet clinical needs and collaborates with global pharmaceutical and biotech companies to translate novel biomarkers into ultra-sensitive companion diagnostics (CDx) or IVD assays. *

	Start	2017-06-01 established
	Predecessor	ETH Zürich (ETHZ)
	Industry	ScaiVision software
	Industry 2	single cell analysis
	Person	Nestorov, Peter (Scailyte 201901 CEO + Co-Founder)
	Person 2	Flores-Candia, Juana Lucia (Scailyte 202209 VP Strategy + Business Development)

	Region	Sursee LU
	Country	Switzerland
	Street	35 Lichtstr.
	City	4056 Basel
		Address record changed: 2024-01-05

Basic data	Employees	B: 11 to 50 (2022-09-19)

		* Document for »About Section«: Scailyte AG. (9/19/22). "Press Release: Scailyte Closes Series A Funding with a CHF 6 Million Investment".

		Record changed: 2023-03-24